These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37747433)

  • 1. Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy.
    Meling Stokland AE; Austdal M; Nedrebø BG; Carlsen S; Hetland HB; Breivik L; Ueland HO; Watt T; Cramon PK; Løvås K; Husebye ES; Ueland GÅ
    J Clin Endocrinol Metab; 2024 Feb; 109(3):827-836. PubMed ID: 37747433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
    Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
    Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
    [No Abstract]   [Full Text] [Related]  

  • 3. Radioiodine therapy versus antithyroid medications for Graves' disease.
    Ma C; Xie J; Wang H; Li J; Chen S
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Audit of long-term treatment outcomes of thyrotoxicosis in a single-centre virtual clinic: The utility of long-term antithyroid drugs.
    Levy MJ; Reddy N; Price D; Bhake R; Bremner E; Barrowcliffe M; Kieffer V; Robinson C; Zaccardi F; Howlett TA
    Clin Endocrinol (Oxf); 2022 Nov; 97(5):643-653. PubMed ID: 35274339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
    Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
    Chen DY; Chen TH
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tale of radioiodine and Graves' orbitopathy.
    Ponto KA; Zang S; Kahaly GJ
    Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
    Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
    Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease.
    Ueland GÅ; Ueland HO; Stokland AM; Bhan A; Schønberg A; Sollid ST; Morgas DE; Holmøy T; Lima K; Methlie P; Løvås K; Torkildsen Ø; Husebye ES
    J Clin Endocrinol Metab; 2024 Jan; 109(2):344-350. PubMed ID: 37708353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study.
    Fung MHM; Lang BHH
    Eur Radiol; 2023 Sep; 33(9):6534-6544. PubMed ID: 37036479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.
    Okosieme OE; Taylor PN; Evans C; Thayer D; Chai A; Khan I; Draman MS; Tennant B; Geen J; Sayers A; French R; Lazarus JH; Premawardhana LD; Dayan CM
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):278-287. PubMed ID: 30827829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Graves' hyperthyroidism: present and future.
    Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graves' disease in childhood.
    Kraiem Z; Newfield RS
    J Pediatr Endocrinol Metab; 2001 Mar; 14(3):229-43. PubMed ID: 11308041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Graves' Disease Patients Following Antithyroid Drugs, Radioactive Iodine, or Thyroidectomy as the First-line Treatment.
    Liu X; Wong CKH; Chan WWL; Tang EHM; Woo YC; Lam CLK; Lang BHH
    Ann Surg; 2021 Jun; 273(6):1197-1206. PubMed ID: 33914484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graves' Disease: Can It Be Cured?
    Wiersinga WM
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):29-38. PubMed ID: 30912336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial.
    Watt T; Cramon P; Bjorner JB; Bonnema SJ; Feldt-Rasmussen U; Gluud C; Gram J; Hansen JL; Hegedüs L; Knudsen N; Bach-Mortensen P; Nolsøe R; Nygaard B; Pociot F; Skoog M; Winkel P; Rasmussen AK
    Trials; 2013 Apr; 14():119. PubMed ID: 23782950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.
    Yang D; Xue J; Ma W; Liu F; Fan Y; Rong J; Yang A; Yu Y
    Nucl Med Commun; 2018 Jan; 39(1):16-21. PubMed ID: 29040161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.
    Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.